Advances in drug discovery and development for pediatric tuberculosis

Mini-Reviews in Medicinal Chemistry

Volumn 16, Issue 6, 2016, Pages 481-497

  Hoagland, Daniel ^a,b   Zhao, Ying ^a   Lee, Richard E ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Pediatric tuberculosis; Tuberculosis; Tuberculosis drug discovery

Indexed keywords

AMIKACIN; AMOXICILLIN; BEDAQUILINE; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GAMMA INTERFERON; IMIPENEM; INTERLEUKIN 12; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETINOID X RECEPTOR; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D RECEPTOR; TUBERCULOSTATIC AGENT;

ARTHRITIS; ARTICLE; BONE MARROW SUPPRESSION; CHEMISTRY; CHILD; CONVULSION; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG FORMULATION; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DYSGLYCEMIA; EPIDEMIC; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART VENTRICLE ARRHYTHMIA; HEPATITIS; HUMAN; HYPERSENSITIVITY; LACTIC ACIDOSIS; LIVER DISEASE; LIVER TOXICITY; METALLIC TASTE; MULTIDRUG RESISTANT TUBERCULOSIS; NEPHROTOXICITY; NEURITIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PSYCHOSIS; QT PROLONGATION; RASH; SKIN DISCOLORATION; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; TUBERCULOSIS; WEAKNESS; ANIMAL; ANTIBIOTIC RESISTANCE; DRUG DEVELOPMENT; DRUG EFFECTS; MYCOBACTERIUM; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; CHILD; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84961616364     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150722101723     Document Type: Article

References (173)

1. Seddon, J.A.; D. Shingadia. Epidemiology and disease burden of tuberculosis in children: a global perspective. Inf. Drug Res., 2014, 7, 153-165.
2. WHO. WHO Global Tuberculosis Report 2014. 2014; Available from: http://www.who.int/tb/publications/global_report/en/.
3. Esmail, H.; et al., The ongoing challenge of latent tuberculosis. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2014, 19, 369(1645), 20130437.
4. Loebel, R.O.; E. Shorr; Richardson, H.B. The Influence of Adverse Conditions upon the Respiratory Metabolism and Growth of Human Tubercle Bacilli. J. Bacteriol., 1933, 26(2), 167-200.
5. Shleeva, M.O., et al., Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis (Edinb), 2011, 91(2), 146-54.
6. Zhang, Y.; Yew W.W.; Barer M.R. Targeting persisters for tuberculosis control. Antimicrob. Agents Chemother., 2012, 56(5), 2223-30.
7. Lienhardt, C. From exposure to disease: the role of environmental factors in susceptibility to and development of tuberculosis. Epidemiol. Rev., 2001, 23(2), 288-301.
8. Merker, M.; et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat. Genet., 2015, advance online publication.
9. Smith, I. Mycobacterium tuberculosis Pathogenesis and Molecular Determin. Virulence. Clin. Microbiol. Rev., 2003, 16(3), 463-496.
10. Starke, J.R. Improving Tuberculosis Care for Children in High- Burden Settings. Pediatrics, 2014, 134(4), 655-657.
11. Basu Roy, R. Current understanding of the immune response to tuberculosis in children. Curr. Opin. Inf. Dis., 2012, 25,250-257.
12. Kumar, N.P.; et al. Suppressed Type 1, Type 2, and Type 17 Cytokine Responses in Active Tuberculosis in Children. Clin. Vacc. Immunol., 2011, 18(11), 1856-1864.
13. Bhat, P.G.; et al. Intensified Tuberculosis Case Finding among Malnourished Children in Nutritional Rehabilitation Centres of Karnataka, India: Missed Opportunities. PLoS One, 2013, 8(12), e84255.
14. Jaganath, D.; E. Mupere. Childhood Tuberculosis and Malnutrition. J. Inf. Dis., 2012, 206(12), 1809-1815.
15. Guelar, A.; et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS, 1993, 7(10), 1345-9.
16. Breen, R.A.M. Tuberculosis and HIV Co-Infection: A Practical Therapeutic Approach. Drugs, 2006, 66(18), 2299-2308.
17. Burger, D.M. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob. Agents Chemother., 1993, 37(7), 1426-1432.
18. Heidari, S., Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. J. Acquired Immun. Deficien. Synd., 2012, 59(2), 7.
19. Niemi, M. Pharmacokinetic Interactions with Rifampicin: Clinical Relevance. Clin. Pharmacokinet., 2003, 42(9), 819-851.
20. Zumla, A.; P. Nahid; S.T. Cole. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov., 2013, 12(5), 388-404.
21. Frydenberg, A.R.; Graham S.M. Toxicity of first-line drugs for treatment of tuberculosis in children: review. Trop. Med. Intl. Health, 2009, 14(11), 1329-1337.
22. Kirimuhuzya, C. Multi-Drug/Extensively Drug Resistant Tuberculosis (Mdr/Xdr-Tb): Renewed Global Battle Against Tuberculosis?, in Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance, D.P.-J. Cardona, Editor. 2012, InTech.
23. Seddon, J.A.; et al. Caring for children with drug-resistant tuberculosis: practice-based recommendations. Am. J. Respir. Crit. Care Med., 2012, 186(10), 953-64.
24. Marais, B.J.; et al. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am. J. Respir. Crit. Care Med., 2006, 173(10), 1078-90.
25. Mandalakas, A.M.; Starke J.R. Current concepts of childhood tuberculosis. Semin. Pediatr. Infect. Dis., 2005, 16(2), 93-104.
26. Schaaf, H.S.; et al. Evaluation of young children in contact with adult multidrug-resistant pulmonary tuberculosis: a 30-month follow-up. Pediatrics, 2002, 109(5), 765-71.
27. Loto, O.M.; I. Awowole, Tuberculosis in Pregnancy: A Review. J. Preg., 2012, 2012.
28. Schaaf, H.S.; et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch. Dis. Childhood, 2005, 90(6), 614-618.
29. Holdiness, M.R.; Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet., 1984, 9(6), 511-44.
30. Corrigan, D.; J. Paton. Hepatic enzyme abnormalities in children on triple therapy for tuberculosis. Pediatr. Pulmonol., 1999, 27(1), 37-42.
31. Chien, S.; et al. Levofloxacin pharmacokinetics in children. J. Clin. Pharmacol., 2005, 45(2), 153-60.
32. Capparelli, E.V.; et al. Pharmacokinetics of Gatifloxacin in Infants and Children. Antimicrob. Agents Chemother., 2005, 49(3),1106-1112.
33. Organization, W.H. Rapid advice: treatment of tuberculosis in children, 2010, WHO: Geneva.
34. Hiruy, H.; et al. Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study. J. Antimicrob. Chemother., 2014
35. Yew, W.W; Leung C.C. Antituberculosis drugs and hepatotoxicity. Respirology, 2006, 11(6), 699-707.
36. Tostmann, A.; et al., Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J. Gastroenterol. Hepatol., 2008, 23(2), 192-202.
37. Oeltmann, J.E.; et al. Reported childhood tuberculosis treatment outcomes, Gaborone and Francistown, Botswana, 1998-2002. Intl. J. Tuberc. Lung Dis., 2008, 12(2), 186-92.
38. Biehl, J.; R.W. Vilter. EFfects of isoniazid on pyridoxine metabolism. J. Am. Med. Ass., 1954, 156(17), 1549-1552.
39. Pellock, J.M.; et al. PYridoxine deficiency in children treated with isoniazid. Chest, 1985, 87(5), 658-661.
40. Possuelo, L.G.; et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur. J. Clin. Pharmacol., 2008, 64(7), 673-81.
41. Lobato, M.N.; Jereb, J.A.; Starke, J.R. Unintended consequences: mandatory tuberculin skin testing and severe isoniazid hepatotoxicity. Pediatrics, 2008, 121(6), e1732-3.
42. Palusci, V.J.; O'Hare, D.; Lawrence, R.M. Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children. Pediatr. Infect. Dis. J., 1995, 14(2), 144-8.
43. Group, P.T.C. Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents. Pediatrics, 2004, 114(Supplement 4), 1175-1201.
44. Desrochers, D.; et al. Isoniazid-Induced Severe Hepatotoxicity: An Infrequent but Preventable Cause of Liver Failure in Children Treated for Latent Tuberculosis Infection. Clinical Medicine Insights. Pediatrics, 2011, 5, 9-13.
45. Wu, S.S.; et al., Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. Transplantation, 2007, 84(2), 173-9.
46. Schuetz, E. P-glycoprotein: A major determinant of rifampicininducible expression of cytochrome P4503A in mice and humans. Proc. Nat. Acad. Sci. U.S.A., 1996, 93, 4001-4006.
47. Williamson, B. Induction of Influx and Efflux Transporters and Cytochrome p4503A4 in Primary Human Hepatocytes by Rifampicin, Rifabutin, and Rifapentine. Antimicrob. Agents Chemother., 2013.
48. Gallicano, K. Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients. Br. J. Clin. Pharmacol., 1999, 48, 168-178.
49. Weiner, M. Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin. Antimicrob. Agents Chemother., 2007, 51(8), 2861-2867.
50. Kuypers, D. Drug Interaction between mycophenolate mofetil and rifampin: Possible induction of uridine diphosphateglucuronosyltransferase. Clin. Pharmacol. Ther., 2005, 78, 81-88.
51. Shi, W.; et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy. Science (New York, N.Y.), 2011, 333(6049), 1630-1632.
52. Zhang, Y.; Mitchison D. The curious characteristics of pyrazinamide: a review. Intl. J. Tuberc. Lung Dis., 2003, 7(1), 6-21.
53. Sanchez-Albisua, I., et al. Tolerance of pyrazinamide in short course chemotherapy for pulmonary tuberculosis in children. Pediatr. Infect. Dis. J., 1997, 16(8), 760-3.
54. Graham, S.M., et al. Low levels of pyrazinamide and ethambutol in children with tuberculosis and impact of age, nutritional status, and human immunodeficiency virus infection. Antimicrob, Agents Chemother, 2006, 50(2), 407-13.
55. Trebucq, A. Should ethambutol be recommended for routine treatment of tuberculosis in children? A review of the literature. Intl. J. Tuberc. Lung Dis., 1997, 1(1), 12-5.
56. WHO, Ethambutol efficacy and toxicity: literature review and recommendations for daily and intermittent dosage in children. 2006.
57. Donald, P.R.; Schaaf, H.S. Old and new drugs for the treatment of tuberculosis in children. Paediatr. Respir. Rev., 2007, 8(2), 134-41.
58. Levy, M., et al. Ethambutol-related Impaired Visual Function in Childrens Less than 5 Years of Age Treated for a Mycobacterial Infection: Diagnosis and Evolution. Pediatr. Infect. Dis. J., 2015, 34(4), 346-50.
59. Ettehad, D., et al. Treatment outcomes for children with multidrugresistant tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis., 12(6), 449-456.
60. Grosset, J.H., Singer T.G.; Bishai, W.R. New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]. Intl. J. Tuberc. Lung Dis., 2012, 16(8), 1005-1014.
61. Raviglione, M.; et al. Scaling up interventions to achieve global tuberculosis control: progress and new developments. Lancet, 2012, 379(9829), 1902-1913.
62. Wong, E.B., Cohen, K.A; Bishai, W.R. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol., 2013, 21(9), 493-501.
63. Zumla, A.I.; et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect. Dis., 2014, 14(4), 327-340.
64. Tasneen, R., Sterilizing Activity of Novel TMC207- and PA-824- Containing Regimens in a Murine Model of Tuberculosis. Antimicrob. Agents Chemother., 2011, 55(12), 5485-5493.
65. Balasubramanian, V. Effect of Coadministration of Moxifloxacin and Rifampin on the Mycobacterium tuberculosis in a Murine Aersol Infection Model. Antimicrob. Agents Chemother., 2012, 56(6), 3054-3058.
66. Schaaf, H.S.; et al. Managing multidrug-resistant tuberculosis in children: review of recent developments. Curr. Opin. Infect. Dis., 2014, 27(3), 211-9.
67. Treluyer, J.M., et al. Nonparametric Population Pharmacokinetic Analysis of Amikacin in Neonates, Infants, and Children. Antimicrob. Agents Chemother., 2002, 46(5), 1381-1387.
68. Peloquin, C.A.; et al. Aminoglycoside toxicity: daily versus thriceweekly dosing for treatment of mycobacterial diseases. Clin. Infect. Dis., 2004, 38(11), 1538-44.
69. Seddon, J.A.; et al. Paediatric use of second-line anti-tuberculosis agents: a review. Tuberculosis (Edinb), 2012, 92(1), 9-17.
70. Kam, K.M.; et al. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist., 2006,12(1), 7-11.
71. Yassin, M.A.; et al. Can Interferon-Gamma or Interferon-Gamma- Induced-Protein-10 Differentiate Tuberculosis Infection and Disease in Children of High Endemic Areas? PLoS One, 2011, 6(9), e23733.
72. Handzel, Z.T. The Immune Response to Mycobacterium Tuberculosis Infection in Humans. 2013: INTECH Open Access Publisher.
73. Lewinsohn, D.A.; et al. Tuberculosis immunology in children: diagnostic and therapeutic challenges and opportunities. Intl. J. Tuberc. Lung Dis., 2004, 8(5), 658-74.
74. Sepulveda, R.L.; et al. Effect of human newborn BCG immunization on monocyte viability and function at 3 months of age. Intl. J. Tuberc. Lung Dis., 1997, 1(2), 122-7.
75. Swaminathan, S.; et al. Cytokine production in children with tuberculous infection and disease. Clin. Infect. Dis., 1999, 28(6), 1290-3.
76. Kleinsteuber, K.; et al. Decreased Expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4+ T Cells and Peripheral Blood from Tuberculosis Patients. PLoS One, 2013, 8(4), e61609.
77. Black, R.E.; et al. Maternal and child undernutrition: global and regional exposures and health consequences. Lancet, 2008, 371(9608), 243-60.
78. Walker, V.P.; R.L. Modlin. The vitamin D connection to pediatric infections and immune function. Pediatr. Res., 2009, 65(5 Pt 2), 106R-113R.
79. Luong, K.; L.T. Nguyen. Impact of vitamin D in the treatment of tuberculosis. Am. J. Med. Sci., 2011, 341(6), 493-8.
80. Levy, O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat. Rev. Immunol., 2007, 7(5), 379-90.
81. Burl, S.; et al. Age-Dependent Maturation of Toll-Like Receptor- Mediated Cytokine Responses in Gambian Infants. PLoS ONE, 2011, 6(4), e18185.
82. Newburg, D.S.; Walker, W.A. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res, 2007, 61(1), 2-8.
83. Dornelles, C.T.L.; Piva, J.P.; Marostica, P.J.C. Nutritional Status, Breastfeeding, and Evolution of Infants with Acute Viral Bronchiolitis. J. Health Pop. Nut., 2007, 25(3), 336-343.
84. Liu, F.; et al., Impact of Glutathione S-Transferase M1 and T1 on Anti-Tuberculosis Drug–Induced Hepatotoxicity in Chinese Pediatric Patients. PLoS ONE, 2014, 9(12), e115410.
85. Strolin Benedetti, M.; Baltes, E.L. Drug metabolism and disposition in children. Fundam. Clin. Pharmacol., 2003, 17(3), 281-99.
86. Butler, D.R.; Kuhn, R.J.; Chandler, M.H. Pharmacokinetics of antiinfective agents in paediatric patients. Clin. Pharmacokinet., 1994, 26(5), 374-95.
87. Harmonisation, I.C.O., Clinical investigation of medicinal products in the pediatric population E11 2000.
88. Wagner, J.; Abdel-Rahman, S.-M. Pediatric Pharmacokinetics. Pediatr. Rev., 2013, 34(6), 258-269.
89. Stewart, C.F.; Hampton, E.M. Effect of maturation on drug disposition in pediatric patients. Clin. Pharm., 1987, 6(7), 548-64.
90. Pacifici, G.M. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur. J. Clin. Pharmacol., 2009, 65(4), 419-27.
91. Huang, N.N.; High, R.H. Comparison of serum levels following the administration of oral and parenteral preparations of penicillin to infants and children of various age groups. J. Pediatr., 42(6), 657-668.
92. Butler, D. Kuhn, R.; Chandler, M.H. Pharmacokinetics of Anti- Infective Agents in Paediatric Patients. Clin. Pharmacokinet., 1994, 26(5), 374-395.
93. Kearns, G.L.; Reed, M.D. Clinical pharmacokinetics in infants and children. A reappraisal. Clin. Pharmacokinet., 1989, 17 Suppl 1, 29-67.
94. Liu, X. Do We Need to Optimize Plasma Protein and Tissue Binding in Drug Discovery. Curr. Top. Med. Chem., 2011, 11, 450-466.
95. Smith, D.A. The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery. Nat. Rev.: Drug Discov., 2010, 9, 11.
96. Dodson, W.E. Special pharmacokinetic considerations in children. Epilepsia, 1987, 28 Suppl 1, S56-70.
97. Cartlidge, P.H.; Rutter, N. Serum albumin concentrations and oedema in the newborn. Arch. Dis. Childhood, 1986, 61(7), 657-660.
98. Kjellsson, M.C.; et al. Pharmacokinetic Evaluation of the Penetration of Antituberculosis Agents in Rabbit Pulmonary Lesions. Antimicrob. Agents Chemother., 2012, 56(1), 446-457.
99. Barclay, W.R.; et al. Distribution and excretion of radioactive isoniazid in tuberculous patients. J. Am. Med. Assoc., 1953, 151(16), 1384-8.
100. Canetti, G.; et al. [Rifomycin levels in the lung and tuberculous lesions in man]. Acta Tuberc. Pneumol. Belg., 1969, 60(3), 315-22.
101. Ellard, G.A.; Humphries, M.J.; Allen, B.W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis., 1993, 148(3), 650-5.
102. Ellard, G.A.; et al. Penetration of pyrazinamide into the cerebrospinal fluid in tuberculous meningitis. Br. Med. J. (Clin. Res. Ed.), 1987, 294(6567), 284-5.
103. Prideaux, B.; et al. High-sensitivity MALDI-MRM-MS imaging of moxifloxacin distribution in tuberculosis-infected rabbit lungs and granulomatous lesions. Anal. Chem., 2011, 83(6), 2112-8.
104. Prideaux, B.; Stoeckli, M. Mass spectrometry imaging for drug distribution studies. J. Proteom., 2012, 75(16), 4999-5013.
105. Seeley, E.H.; Caprioli, R.M. 3D Imaging by Mass Spectrometry: A New Frontier. Analyt. Chem., 2012, 84(5), 2105-2110.
106. Hines, R.N. The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol. Ther., 2008, 118(2), 250-67.
107. Lacroix, D.; et al. Expression of CYP3A in the human liver-- evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem., 1997, 247(2), 625-34.
108. Pflieger, M.; Bertram, D. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan]. Arch. Pediatr., 2014, 21(10), 1129-38.
109. WHO, Dosing instructions for the use of currently available fixeddose combination TB medicines for children, 2009, WHO.
110. Koul, A.; et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol., 2007, 3(6), 323-324.
111. Diacon, A.H.; et al. The diarylquinoline TMC207 for multidrugresistant tuberculosis. N. Engl. J. Med., 2009, 360(23), 2397-405.
112. Andries, K.; et al. A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707), 223-227.
113. Haagsma, A.C.; et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother., 2009, 53(3), 1290-2.
114. Cohen, J.; Approval of Novel TB Drug Celebrated—With Restraint. Science, 2013, 339(6116), 130.
115. Ibrahim, M. Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis. Antimicrob. Agents Chemother., 2006, 51(3), 1011-1016.
116. Diacon, A.H.; et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet, 380(9846), 986-993.
117. Gler, M.T.; et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med., 2012, 366(23), p. 2151-60.
118. Esposito, S.; et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur. Resp. J., 2014, 44(3), 811-815.
119. Stover, C.K.; et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, 405(6789), 962-6.
120. Lenaerts, A.J.; et al. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother., 2005, 49(6), 2294-301.
121. Matsumoto, M.; et al. OPC-67683, a Nitro-Dihydro-Imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med., 2006, 3(11), e466.
122. Diacon, A.H.; et al. Early bactericidal activity of delamanid (OPC- 67683) in smear-positive pulmonary tuberculosis patients. Intl. J. Tuberc. Lung Dis., 2011, 15(7), 949-54.
123. Zhang, M.; et al. In vitro and in vivo activities of three oxazolidinones against nonreplicating mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, 58(6), 3217-3223.
124. Lee, M.; et al. Linezolid for treatment of chronic extensively drugresistant tuberculosis. N. Engl. J. Med., 2012, 367(16), 1508-18.
125. Garcia-Prats, A.J.; et al. Linezolid for the treatment of drugresistant tuberculosis in children: a review and recommendations. Tuberculosis (Edinb), 2014, 94(2), 93-104.
126. Aubry, A.; et al. Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. Antimicrob. Agents Chemother., 2006, 50(1), 104-12.
127. Mdluli, K.; Ma, Z. Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. Infect. Disord. Drug Targets, 2007, 7(2), 159-68.
128. Thee, S.; et al. Fluoroquinolones for the treatment of tuberculosis in children. Tuberculosis, 2015, 95(3), 229-245.
129. Seddon, J.A.; et al. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax, 2014, 69(5), 458-64.
130. Ashtekar, D.R.; et al. Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis. Diagn. Microbiol. Infect. Dis., 1991, 14(6), 465-71.
131. Rose, P.C.; et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Intl. J. Tuberc. Lung Dis., 2012, 16(12), 1588-93.
132. Anger, H.A.; et al. Linezolid use for treatment of multidrugresistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J. Antimicrob. Chemother., 2010, 65(4), 775-83.
133. Wallis, R.S.; et al. Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide. PLoS ONE, 2012, 7(1), e30479.
134. Benator, D.; et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drugsusceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet, 2002, 360(9332), 528-34.
135. Rosenthal, I.M.; et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med., 2007, 4(12), e344.
136. Diacon, A.H.; et al. Early Bactericidal Activity of High-Dose Rifampin in Patients with Pulmonary Tuberculosis Evidenced by Positive Sputum Smears. Antimicrob. Agents Chemother., 2007, 51(8), 2994-2996.
137. Li, W.; et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, 58(11), 6413-23.
138. Sacksteder, K.A.; et al. Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action. Future Microbiol., 2012, 7(7), 823-37.
139. Protopopova, M.; et al. Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2- ethylenediamines. J. Antimicrob. Chemother., 2005, 56(5), 968-74.
140. Jia, L.; et al. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol., 2005, 144(1), 80-7.
141. Biava, M.; Porretta, G.C.; Manetti, F. New derivatives of BM212: A class of antimycobacterial compounds based on the pyrrole ring as a scaffold. Mini. Rev. Med. Chem., 2007, 7(1), 65-78.
142. Li, W., et al. Novel Insights into the Mechanism of Inhibition of MmpL3, a Target of Multiple Pharmacophores in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, 58(11), 6413-6423.
143. Poce, G., et al. Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection. PLoS One, 2013, 8(2), e56980.
144. Li, K.; et al. Multitarget Drug Discovery for Tuberculosis and Other Infectious Diseases. J. Med. Chem., 2014, 57(7), 3126-3139.
145. Paulsen, I.T.; Brown, M.H.; Skurray, R.A. Proton-dependent multidrug efflux systems. Microbiol. Rev., 1996, 60(4), 575-608.
146. Tseng, T.T.; et al. The RND permease superfamily: an ancient, ubiquitous and diverse family that includes human disease and development proteins. J. Mol. Microbiol. Biotechnol., 1999, 1(1), 107-25.
147. Murakami, S. Multidrug efflux transporter, AcrB--the pumping mechanism. Curr. Opin. Struct. Biol., 2008, 18(4), 459-65.
148. Goldman, R.C. Why are membrane targets discovered by phenotypic screens and genome sequencing in Mycobacterium tuberculosis? Tuberculosis (Edinb), 2013, 93(6), 569-88.
149. Grzegorzewicz, A.E.; et al. Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane. Nat. Chem. Biol., 2012, 8(4), 334-341.
150. Mdluli, K.; Kaneko, T.; Upton, A. The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets. Cold Spr. Harb. Perspect. Med., 2015.
151. Stanley, S.A.; et al. Identification of Novel Inhibitors of M. tuberculosis Growth Using Whole Cell Based High-Throughput Screening. ACS Chem. Biol., 2012, 7(8), 1377-1384.
152. Rao, S.P.S.; et al. Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis. Sci. Translat. Med., 2013, 5(214), 214ra168.
153. Deng, J.; et al. Mycobacterium Tuberculosis Proteome Microarray for Global Studies of Protein Function and Immunogenicity. Cell Reports, 2014, 9(6), 2317-2329.
154. Brown, J.R.; et al. The structure-activity relationship of urea derivatives as anti-tuberculosis agents. Bioorg. Med. Chem., 2011, 19(18), 5585-95.
155. Abrahams, K.A.; et al. Identification of Novel Imidazo[1,2- a]pyridine Inhibitors Targeting M. tuberculosis QcrB. PLoS ONE, 2012, 7(12), e52951.
156. Darby, C.M.; et al. Whole Cell Screen for Inhibitors of pH Homeostasis in Mycobacterium tuberculosis. PLoS ONE, 2013, 8(7), e68942.
157. Kumar, A.; et al. A High-Throughput Screen against Pantothenate Synthetase (PanC) Identifies 3-Biphenyl-4-Cyanopyrrole-2- Carboxylic Acids as a New Class of Inhibitor with Activity against Mycobacterium tuberculosis. PLoS ONE, 2013, 8(11), e72786.
158. Mak, P.A.; et al. A high-throughput screen to identify inhibitors of ATP homeostasis in non-replicating Mycobacterium tuberculosis. ACS Chem. Biol., 2012, 7(7), 1190-7.
159. Christophe, T.; et al. High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. Future Med. Chem., 2010, 2(8), 1283-93.
160. Pethe, K.; et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med., 2013, 19(9), 1157-60.
161. Lee, R.E.; et al. Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux. Nat. Med., 2014, 20(2), 152-158.
162. Makarov, V., et al., Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis. Science, 2009, 324(5928), 801-804.
163. Shirude, P.S., et al. Azaindoles: Noncovalent DprE1 Inhibitors from Scaffold Morphing Efforts, Kill Mycobacterium tuberculosis and Are Efficacious in Vivo. J. Med. Chem., 2013, 56(23), 9701-9708.
164. Johnsson, K.; Schultz, P.G. Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc., 1994, 116(16), 7425-7426.
165. Rozwarski, D.A., et al. Modification of the NADH of the Isoniazid Target (InhA) from Mycobacterium tuberculosis. Science, 1998, 279(5347), 98-102.
166. Lu, X.; You Q.; Chen Y. Recent progress in the identification and development of InhA direct inhibitors of Mycobacterium tuberculosis. Mini. Rev. Med. Chem., 2010, 10, 181-192.
167. Šink, R., et al. Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis. J. Med. Chem., 2015, 58(2), 613-624.
168. Ballell Pages, L., et al. (Pyrazol-3-yl)-1,3,4-thiadiazole- 2-amine and (Pyrazol-3-yl)-1,3,4-thiazol-2-amine Compounds. WO 2010118852 A1, 2010.
169. Pethe, K.; et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat. Med., 2013, 19(9), 1157-1160.
170. Katritzky, A.R.; Xu, Y.-J.; Tu, H. Regiospecific Synthesis of 3- Substituted Imidazo[1,2-a]pyridines, Imidazo[1,2-a]pyrimidines, and Imidazo[1,2-c]pyrimidine. J. Org. Chem., 2003, 68(12), 4935-4937.
171. Hu, Q.-H.; et al. Discovery of a potent benzoxaborole-based antipneumococcal agent targeting leucyl-tRNA synthetase. Sci. Rep., 2013, 3.
172. Hurdle, J.G.; O'Neill, A.J.; Chopra, I. Prospects for Aminoacyl-tRNA Synthetase Inhibitors as New Antimicrobial Agents. Antimicrob. Agents Chemother., 2005, 49(12), 4821-4833.
173. Nare, B.; et al. Discovery of novel orally bioavailable oxaborole 6- carboxamides that demonstrate cure in a murine model of late-stage central nervous system african trypanosomiasis. Antimicrob. Agents Chemother., 2010, 54(10), 4379-88.